REVIEW article
Front. Microbiol.
Sec. Infectious Agents and Disease
This article is part of the Research TopicPathogenic Gammaproteobacteria: Novel Insights into Virulence Mechanisms and Therapeutic InterventionView all 10 articles
Biological Treatments for Zoonotic Salmonellosis: An Evolving Therapeutic Landscape
Provisionally accepted
- 1Assumption University, Bangkok, Thailand
- 2Chengdu Medical College, Chengdu, China
- 3Qinghai University, Xining, China
- 4Shaoxing People's Hospital, Shaoxing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Salmonellosis, a predominant food-borne gastroenteric disease, presents a substantial and escalating threat to global public health, largely attributable to infections by nontyphoidal Salmonella serovars such as Salmonella enterica serovar Typhimurium (S. Typhimurium) and Salmonella serovar Enteritidis (S. Enteritidis). The conventional reliance on antimicrobial agents for treating salmonellosis is increasingly compromised by the emergence and spread of multidrug-resistant (MDR) strains, necessitating an urgent shift towards alternative therapeutic strategies. In recent years, biological therapies, including bacteriophages, probiotics, vaccines and their synergistic combinations, have demonstrated considerable promise. Advances in antibacterial research highlight the potential of biotherapies to offer high efficacy with minimal side effects. This review consolidates the most current information on the methodologies, mechanisms of action, functional benefits, and clinical research progress of these biological treatments in combating zoonotic salmonellosis. We delve into recent innovations such as engineered phages and probiotics, postbiotics, novel vaccine platforms including mRNA and nanoparticle-based delivery systems, and the development of multivalent vaccines. Furthermore, the importance of the One Health perspective in controlling salmonellosis and the translational challenges, including regulatory and commercialization hurdles, are discussed. It is anticipated that biotherapies, particularly engineered and combination approaches, hold significant potential for addressing the challenge of MDR bacteria and safeguarding public and animal health.
Keywords: Bacteriophages, Biotherapies, Probiotics, Salmonella, salmonellosis, Vaccines
Received: 21 Dec 2025; Accepted: 29 Jan 2026.
Copyright: © 2026 Ma, Liu, Shen, Deng, Chengxiang, Yang, Zhang and JIa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xu JIa
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.